These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 22483497

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
    Papadopoulos-Köhn A, Achterfeld A, Paul A, Canbay A, Timm J, Jochum C, Gerken G, Herzer K.
    Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [The recurrence of hepatitis C virus after liver transplantation].
    Nemes B, Sárváry E, Gerlei Z, Fazakas J, Doros A, Németh A, Görög D, Fehérvári I, Máthé Z, Gálffy Z, Pár A, Schuller J, Telegdy L, Fehér J, Lotz G, Schaff Z, Nagy P, Járay J, Lengyel G.
    Orv Hetil; 2007 Oct 21; 148(42):1971-9. PubMed ID: 17932003
    [Abstract] [Full Text] [Related]

  • 27. Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report.
    Yamamoto T, Tanaka S, Uenishi T, Kanazawa A, Kubo S, Hirohashi K.
    Osaka City Med J; 2014 Dec 21; 60(2):95-100. PubMed ID: 25803885
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation.
    Van Wagner LB, Baker T, Ahya SN, Norvell JP, Wang E, Levitsky J.
    J Hepatol; 2009 Nov 21; 51(5):874-80. PubMed ID: 19643508
    [Abstract] [Full Text] [Related]

  • 30. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible?
    Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E, Leroy V.
    J Clin Virol; 2013 Feb 21; 56(2):146-9. PubMed ID: 23149155
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation.
    Terrault NA, Shiffman ML, Lok AS, Saab S, Tong L, Brown RS, Everson GT, Reddy KR, Fair JH, Kulik LM, Pruett TL, Seeff LB, A2ALL Study Group.
    Liver Transpl; 2007 Jan 21; 13(1):122-9. PubMed ID: 17192908
    [Abstract] [Full Text] [Related]

  • 33. Interferon-Free Sofosbuvir-Based Anti-HCV Therapy After Liver Transplantation.
    Seifert LL, Vorona E, Bester C, Stahl M, Hüsing A, Beckebaum S, Kabar I, Heinzow H, Schmidt HH.
    Ann Transplant; 2015 Sep 22; 20():561-8. PubMed ID: 26391423
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Genotype 3 and higher low-density lipoprotein levels are predictors of good response to treatment of recurrent hepatitis C following living donor liver transplantation.
    Saigal S, Choudhary NS, Saraf N, Gautam D, Lipi L, Rastogi A, Goja S, Menon PB, Bhangui P, Ramachandra SK, Soin AS.
    Indian J Gastroenterol; 2015 Jul 22; 34(4):305-9. PubMed ID: 26394853
    [Abstract] [Full Text] [Related]

  • 36. Preemptive therapy for hepatitis C virus after living-donor liver transplantation.
    Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, Kokudo N.
    Transplantation; 2004 Nov 15; 78(9):1308-11. PubMed ID: 15548968
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.